Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer

Study population

We studied three independent cohorts of patients with NSCLC who were treated with PD-1-based immunotherapies in the advanced or metastatic setting. The clinical characteristics of the cohorts are presented in Supplementary Tables